J. F. Huggett, C. A. Foy, V. Benes, K. Emslie, J. A. Garson et al., The digital MIQE guidelines: Minimum Information for Publication of Quantitative Digital PCR Experiments, Clinical chemistry, vol.59, issue.6, pp.892-902, 2013.

B. Vogelstein, K. W. Kinzler, and P. Digital, Proc Natl Acad Sci U S A, vol.96, issue.16, p.17763, 1999.

P. J. Sykes, S. H. Neoh, M. J. Brisco, E. Hughes, J. Condon et al., Quantitation of targets for PCR by use of limiting dilution, BioTechniques, vol.13, issue.3, pp.444-453, 1992.

V. Taly, D. Pekin, A. El-abed, and P. Laurent-puig, Detecting biomarkers with microdroplet technology, Trends Mol Med, vol.18, issue.7, pp.405-421, 2012.
URL : https://hal.archives-ouvertes.fr/inserm-02299585

P. Laurent-puig, D. Pekin, C. Normand, S. K. Kotsopoulos, P. Nizard et al., Clinical relevance of KRAS-mutated subclones detected with picodroplet digital PCR in advanced colorectal cancer treated with anti-EGFR therapy, Clin Cancer Res, vol.21, issue.5, 2015.

M. Watanabe, T. Kawaguchi, S. I. Isa, M. Ando, A. Tamiya et al., Ultra-Sensitive Detection of the Pretreatment EGFR T790M Mutation in Non-Small Cell Lung Cancer Patients with an EGFR-Activating Mutation Using Droplet Digital PCR, Epub 2015/04/18, 2015.

D. S. Guttery, K. Page, A. Hills, L. Woodley, S. D. Marchese et al., Noninvasive Detection of Activating Estrogen Receptor 1 (ESR1) Mutations in Estrogen Receptor-Positive Metastatic Breast Cancer, Epub 2015/05/17, vol.61, p.25979954, 2015.

V. Taly, D. Pekin, L. Benhaim, S. K. Kotsopoulos, L. Corre et al., Multiplex picodroplet digital PCR to detect KRAS mutations in circulating DNA from the plasma of colorectal cancer patients, Clinical chemistry, vol.59, issue.12, 2013.
URL : https://hal.archives-ouvertes.fr/inserm-02299581

Q. Wang, X. Yang, Y. He, L. Ma, and P. Fu, Droplet Digital PCR for Absolute Quantification of EML4-ALK Gene Rearrangement in Lung Adenocarcinoma, J Mol Diagn, 2015.

K. Perez-toralla, D. Pekin, J. F. Bartolo, F. Garlan, P. Nizard et al., Digital PCR compartmentalization I. Single-molecule detection of rare mutations, vol.31, pp.84-92, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02299576

O. Caen, P. Nizard, S. Garrigou, K. Perez-toralla, E. Zonta et al.,

M. , Medecine, vol.31, issue.2, pp.180-186, 2015.

E. Heitzer, P. Ulz, and J. B. Geigl, Circulating tumor DNA as a liquid biopsy for cancer, Clinical chemistry, vol.61, issue.1, pp.112-135, 2015.

G. Francis and S. Stein, Circulating Cell-Free Tumour DNA in the Management of Cancer, Int J Mol Sci, vol.16, issue.6, p.4490543, 2015.

S. C. Tsao, J. Weiss, C. Hudson, C. Christophi, J. Cebon et al., Monitoring response to therapy in melanoma by quantifying circulating tumour DNA with droplet digital PCR for BRAF and NRAS mutations, Scientific reports, vol.5, 2015.

P. Central and P. , , p.4476039

J. Y. Douillard, G. Ostoros, M. Cobo, T. Ciuleanu, R. Cole et al., Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status, vol.9, p.4224589, 2014.

A. Nishiyama, N. Katakami, H. Yoshioka, M. Iwasaku, Y. Korogi et al., Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non-squamous non-small-cell lung cancer. Lung Cancer, Epub 2015/07/ 05, 2015.

J. F. Gainor and A. T. Shaw, Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer, J Clin Oncol, vol.31, issue.31, p.3805932, 2013.

E. Massarelli, F. M. Johnson, H. S. Erickson, I. I. Wistuba, and V. Papadimitrakopoulou, Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance, Lung Cancer, vol.80, issue.3, p.23485129, 2013.

T. K. Yung, K. C. Chan, T. S. Mok, J. Tong, K. F. To et al., Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients, Clin Cancer Res, vol.15, issue.6, pp.2076-84, 2009.

M. Juchum, M. Gunther, and S. A. Laufer, Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors, vol.20, pp.12-28, 2015.

A. Lievre, J. B. Bachet, V. Boige, A. Cayre, L. Corre et al., KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab, J Clin Oncol, vol.26, issue.3, pp.374-383, 2008.
URL : https://hal.archives-ouvertes.fr/hal-00363737

D. Tougeron, T. Lecomte, J. C. Pages, C. Villalva, C. Collin et al., Effect of low-frequency KRAS mutations on the response to anti-EGFR therapy in metastatic colorectal cancer, Medical Oncology / ESMO, vol.24, issue.5, pp.1267-73, 2013.

A. Lievre, J. B. Bachet, L. Corre, D. Boige, V. Landi et al., KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer, Cancer Res, vol.66, issue.8, pp.3992-3997, 2006.

D. Zheng, R. Wang, Y. Zhang, Y. Pan, X. Cheng et al., The prevalence and prognostic significance of KRAS mutation subtypes in lung adenocarcinomas from Chinese populations, OncoTargets and therapy, vol.9, p.4768896, 2016.

J. Huang, J. M. Lohr, M. Nilsson, R. Segersvard, H. Matsson et al., Variant Profiling of Candidate Genes in Pancreatic Ductal Adenocarcinoma, Clinical chemistry, vol.61, issue.11, 2015.

A. Didelot, L. Corre, D. Luscan, A. Cazes, A. Pallier et al., Competitive allele specific TaqMan PCR for KRAS, BRAF and EGFR mutation detection in clinical formalin fixed paraffin embedded samples. Experimental and molecular pathology, vol.92, 2012.

M. J. Duffy, N. C. Synnott, P. M. Mcgowan, J. Crown, D. O'connor et al., p53 as a target for the treatment of cancer, Cancer treatment reviews, vol.40, issue.10, 2014.

J. Li, L. Yang, S. Gaur, K. Zhang, X. Wu et al., Mutants TP53 p.R273H and p.R273C but not p. R273G enhance cancer cell malignancy, Hum Mutat, vol.35, issue.5, p.24677579, 2014.

Y. Zhang, Y. J. Zhang, H. Y. Zhao, Q. L. Zhai, Y. Zhang et al., The impact of R213 mutation on p53-mediated p21 activity, Biochimie, vol.99, pp.215-223, 2014.

E. Zonta, P. Nizard, and V. Taly, Assessment of DNA Integrity, Applications for Cancer Research, Advances in clinical chemistry, vol.70, pp.197-246, 2015.
URL : https://hal.archives-ouvertes.fr/inserm-02299567

C. A. Milbury, Determining lower limits of detection of digital PCR assays for cancer-related gene mutations. Biomolecular Detection and Quantification, vol.1, pp.8-22, 2014.

A. , C. Pantel, and K. , Circulating tumor cells: liquid biopsy of cancer, Clinical chemistry, vol.59, issue.1, pp.110-118, 2013.

D. Zheng, X. Ye, M. Z. Zhang, Y. Sun, J. Y. Wang et al., Plasma EGFR T790M ctDNA status is associated with clinical outcome in advanced NSCLC patients with acquired EGFR-TKI resistance, Scientific reports, vol.6, p.4751431, 2016.

X. Yang, M. Zhuo, X. Ye, H. Bai, Z. Wang et al., Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer, Oncotarget, 2016.

C. Bettegowda, M. Sausen, R. J. Leary, I. Kinde, Y. Wang et al., Detection of circulating tumor DNA in early-and late-stage human malignancies, Science translational medicine, vol.6, issue.224, p.24553385, 2014.

P. Central and P. , , p.4017867

Q. Zhong, S. Bhattacharya, S. Kotsopoulos, J. Olson, V. Taly et al., Multiplex digital PCR: breaking the one target per color barrier of quantitative PCR, Lab Chip, vol.11, issue.13, 2011.
URL : https://hal.archives-ouvertes.fr/inserm-02299588